These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 364952)

  • 1. New hypolipidemic drugs.
    Bencze WL
    Adv Exp Med Biol; 1978; 109():77-95. PubMed ID: 364952
    [No Abstract]   [Full Text] [Related]  

  • 2. The effect of hypolipidemic drugs on plasma lipoproteins.
    Levy RI
    Annu Rev Pharmacol Toxicol; 1977; 17():499-510. PubMed ID: 326171
    [No Abstract]   [Full Text] [Related]  

  • 3. [Serum lipoproteins and antilipemic drugs related to clofibrate. Their in vitro interaction].
    Beaumont JL; Dachet C
    Atherosclerosis; 1973; 17(3):419-33. PubMed ID: 4351719
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of drugs on postprandial lipoprotein metabolism.
    Packard CJ
    Proc Nutr Soc; 1997 Jul; 56(2):745-51. PubMed ID: 9264125
    [No Abstract]   [Full Text] [Related]  

  • 5. [Fibrates: mechanism of action, effect on levels of lipids and lipoproteins, risk of coronary events. Part 1. Clofibrate, gemfibrosil, besafibrate].
    Dobordzhginidze LM; Gratsianskiĭ NA
    Kardiologiia; 2004; 44(2):96-103. PubMed ID: 15125434
    [No Abstract]   [Full Text] [Related]  

  • 6. Newer hypolipidemic compounds.
    Kritchevsky D
    Adv Exp Med Biol; 1975; 63():135-50. PubMed ID: 1106139
    [No Abstract]   [Full Text] [Related]  

  • 7. A new multifunctional hydroxytyrosol-clofibrate with hypolipidemic, antioxidant, and hepatoprotective effects.
    Xie YD; Chen ZZ; Shao LH; Wang QT; Li N; Lu WF; Xu YH; Gao YQ; Guo LY; Liu HL; Li YP; Yang GD; Bian XL
    Bioorg Med Chem Lett; 2018 Oct; 28(18):3119-3122. PubMed ID: 30119959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of S-8527 (1,1-bis(4'-(1'-carboxy-1'-methylpropoxy)phenyl) cyclohexane), a new hypolipidemic compound, on cholesterol and lipoprotein metabolism in rats.
    Suzuki K
    Biochem Pharmacol; 1976 Feb; 25(3):325-8. PubMed ID: 1267828
    [No Abstract]   [Full Text] [Related]  

  • 9. The mechanism of action of lipid-lowering drugs.
    LaRosa JC
    Angiology; 1982 Sep; 33(9):562-76. PubMed ID: 7125296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Experimental research on the action of a derivative from a p-chloropenoxyisobutyric acid series on lipid parameters].
    Filip M; Hriscu A; Păduraru I; Rusu M
    Rev Med Chir Soc Med Nat Iasi; 1986; 90(1):156-60. PubMed ID: 3764166
    [No Abstract]   [Full Text] [Related]  

  • 11. [Comparative effects of clofibrate and tiadenol on the metabolism of cholesterol in rats and hamsters. I. Comparative action of clofibrate and tiadenol on hepatic and intestinal biosynthesis of cholesterol in hamsters and rats].
    Rousselet F; Fredj G; Clenet M
    Ann Pharm Fr; 1986; 44(4):269-76. PubMed ID: 3566092
    [No Abstract]   [Full Text] [Related]  

  • 12. Arterial cholesterol esterase.
    Kritchevsky D
    Adv Exp Med Biol; 1977; 82():878-81. PubMed ID: 920445
    [No Abstract]   [Full Text] [Related]  

  • 13. Studies on hypolipidemic agents. V. Influence of 5-tridecylpyrazole-3-carboxylic acid, a new hypolipidemic agent, on intestinal cholesterol absorption in rats.
    Seki K; Watanabe T; Suga T
    Chem Pharm Bull (Tokyo); 1988 Mar; 36(3):1117-21. PubMed ID: 3409399
    [No Abstract]   [Full Text] [Related]  

  • 14. Results of treatment of hyperlipidemias: long-term compliance and effect of lipid metabolism.
    Frantz ID
    Adv Exp Med Biol; 1977; 82():649-55. PubMed ID: 920422
    [No Abstract]   [Full Text] [Related]  

  • 15. Antilipolytic effect of tiadenol and clofibrate in rat epididymal fat pads.
    Bacciarelli C; Boni P; Castellucci A
    Farmaco Prat; 1978 Sep; 33(9):401-6. PubMed ID: 218836
    [No Abstract]   [Full Text] [Related]  

  • 16. Catalase levels in Drosophila and the lack of induction by hypolipidemic compounds. A brief note.
    Massie HR; Baird MB
    Mech Ageing Dev; 1976; 5(1):39-43. PubMed ID: 817092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypolipidemic drugs.
    Sirtori C; Fumagalli R; Paoletti R
    Adv Exp Med Biol; 1973; 38():171-98. PubMed ID: 4594063
    [No Abstract]   [Full Text] [Related]  

  • 18. The effect of hypolipidemic agents on the hepatic microsomal drug-metabolizing enzyme system of the rat. Induction of cytochrome(s) P-450 with specificity toward terminal hydroxylation of lauric acid.
    Orton TC; Parker GL
    Drug Metab Dispos; 1982; 10(2):110-5. PubMed ID: 6124394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New chitosan salt in gastro-resistant oral formulation could interfere with enteric bile salts emulsification of diet fats: preliminary laboratory observations and physiologic rationale.
    Fratter A; Frare C; Uras G; Bonini M; Casari Bariani E; Ragazzo B; Gaballo P; Longobardi P; Codemo C; Paoli A
    J Med Food; 2014 Jun; 17(6):723-9. PubMed ID: 24827073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased susceptibility to copper-induced oxidation of rat-lipoproteins after fibrate treatment: influence of fatty acid composition.
    Vázquez M; Merlos M; Adzet T; Laguna JC
    Br J Pharmacol; 1996 Mar; 117(6):1155-62. PubMed ID: 8882610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.